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Background: The contribution of CD8+ lymphocytes to the pathogenesis of cardiac
allograft vasculopathy, or chronic rejection in heart transplants, remains undefined.
We used both major histocompatibility complex class I mismatched and major his-
tocompatibility complex class II mismatched models of cardiac allograft vascu-
lopathy to characterize the role of CD8+ lymphocytes in the development of cardiac
allograft vasculopathy.
Methods: Donor hearts from B10.A mice were transplanted into B10.BR recipients
(major histocompatibility complex class I mismatched). Donor hearts were har-
vested at 1, 7, 14, and 30 days after transplantation and (1) quantitated morphomet-
rically for lesion development, (2) stained immunohistochemically, or (3) digested
for isolation of graft-infiltrating cells. The cytotoxic phenotype of graft-infiltrating
CD8+ lymphocytes was determined with flow cytometry. Intracellular cytokine
staining of CD8+ and CD4+ lymphocytes for interleukin 2, interferon γ, interleukin
4, and interleukin 10 was performed with 2-color flow cytometry. Finally, B6.C-
H2bm12 donor hearts were transplanted into either C57BL/6 wild-type (major histo-
compatibility complex class II mismatched) or CD8 –/– knockout recipients and
examined for the development of cardiac allograft vasculopathy.
Results: In the major histocompatibility complex class I mismatched model, CD8+
lymphocytes were the predominant T-lymphocyte subset that infiltrated the allo-
grafts and demonstrated markers of activation. The intracellular cytokine-staining
assay demonstrated that CD8+ lymphocytes were the primary sources of allograft
interleukin 2 and interferon γ. Intimal lesions developed in the allografts by day 14
(12.0% ± 4.0%) and further increased by day 30 (44.0% ± 5.0%). In the major his-
tocompatibility complex class II mismatched model, the donor hearts in the CD8
–/– knockout recipients had substantially less severe intimal lesions when compared
with the donor hearts in wild-type recipients (19.0% ± 6.0% vs 50.0% ± 7.0%,
respectively; P < .05).
Conclusions: In both major histocompatibility complex class I and II mismatched
models, CD8+ lymphocytes contribute significantly to chronic rejection. The find-
ings of this study suggest that control of chronic rejection requires interventions
directed at CD8+ lymphocytes.
Improved perioperative care and more effective immunosuppression regi-mens have dramatically improved the short-term outcome of heart trans-plantation. However, chronic rejection, or cardiac allograft vasculopathy(CAV), remains the major obstacle to the long-term survival of heart trans-plant recipients.1 Although 3-hydroxy-3-methylglutaryl coenzyme A reduc-tase (HMG-CoA) inhibitors have been reported to decrease the severity of
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intimal proliferation,2 pharmacologic therapies have gener-
ally been ineffective in preventing CAV development.
Because of the diffuse nature of the intimal lesions, revas-
cularization procedures are seldom used. Retransplantation
remains a therapeutic option; however, both poor short-term
outcomes compared with the initial transplantation3 and
scarcity of donor organs pose an ethical dilemma in most
transplant centers.
CAV is a complex multifactorial process. Although the
contribution of alloantigen-independent processes to the
development of CAV is becoming increasingly evident,4 it is
generally accepted that the cellular immune system partici-
pates in the pathogenesis of CAV.5-8 However, the role of T-
lymphocyte subsets, and specifically the role of CD8+
lymphocytes in the development of CAV, is incompletely
defined. Prior studies have yielded conflicting results on the
role of CD8+ lymphocytes in chronic rejection. Allan and
colleagues9 have demonstrated the importance of CD8+ lym-
phocytes in chronic rejection using an inbred porcine major
histocompatibility complex (MHC) class I mismatch model
in which intimal proliferation was abrogated after anti-CD8
antibody therapy. In contrast, Clarke-Forbes and cowork-
ers10 reported that CD8+ lymphocyte depletion did not alter
the severity of chronic rejection in a rat MHC class I and
class II mismatched model. Similarly, using a murine carotid
artery loop model, Shi and colleagues5 reported that CD8+
lymphocytes were not involved in neointimal proliferation.
Our laboratory has previously characterized 2 murine
models of CAV without immunosuppression in which the
donor and recipient strains differ at either (1) MHC class I
or (2) MHC class II antigens.11-13 Using these 2 models, we
sought to define the role of CD8+ lymphocytes in CAV. In
the MHC class I mismatched model we studied (1) the tem-
poral pattern of CD8+ lymphocyte infiltration in relation-
ship to CAV development, (2) the activation status of
infiltrating CD8+ lymphocytes, and (3) the contribution of
CD8+ lymphocytes to the production of proinflammatory
cytokines, including interferon (IFN) γ. Given the availabil-
ity of transgenic strains in our MHC class II mismatched
model, we studied the effect of genetic absence of CD8+
lymphocytes on CAV development. The results of this study
demonstrate an important role for CD8+ lymphocytes in
chronic rejection. More importantly, these findings yield
some insight into the mechanism of failure of costimulatory
blockade therapy in preventing chronic rejection.
Methods
Animals
B10.A, B10.BR, B6.CH-2bm12, and C57BL/6 (wild-type, CD8 –/–
knockout) strains of female mice (7-11 weeks old) were purchased
from Jackson Laboratories and housed under conventional condi-
tions. They were fed rodent chow (Purina Mills, Inc, St Louis, Mo)
and water ad libitum. The B10.A and B10.BR strains of mice differ
at 2 loci of MHC class I antigens but are matched at other loci. The
B6.CH-2bm12 and C57BL/6 strains of mice differ in one locus of
MHC class II antigens but are matched at other loci. All animals
received humane care in compliance with the “Principles of
Laboratory Animal Care” and the “Guide for the Care and Use of
Laboratory Animals” prepared by the Institute of Laboratory Animal
Resources and published by the National Institutes of Health.
Transplantation
The intra-abdominal heterotopic heart transplantation was per-
formed with the technique previously described by Corry and col-
leagues.14 Briefly, through a midline abdominal incision, the donor
aorta was anastomosed to the recipient infrarenal abdominal aorta,
and the donor pulmonary artery was anastomosed to the inferior
vena cava with 10-0 nylon sutures. The donor ischemia time was
approximately 45 minutes. Function of the allografts was assessed
through abdominal palpation and scored on a scale of 0 to 4 (0 indi-
cates absence of contractions and 4 indicates normal beating).
Experimental Groups
In the MHC class I mismatched group B10.A strain mouse hearts
were transplanted into B10.BR recipients and harvested at days 1,
7, 14, and 30, respectively (n = 6 each group). In the isograft
groups B10.BR mouse hearts were transplanted into B10.BR
recipients and removed at days 1, 7, 14, and 30 (n = 6 each group).
Control B10.A and B10.BR hearts were also excised (day 0) and
examined for infiltration of inflammatory cells and constitutive
expression of activation markers (n = 6 each group). No immuno-
suppression was administered.
In the MHC class II mismatched group B6.CH-2bm12 mouse
hearts were transplanted into C57BL/6 wild-type control recipi-
ents (n = 6) or CD8 –/– knockout recipients (n = 6). In the isograft
groups C57BL/6 mouse hearts were transplanted into C57BL/6
recipients (n = 6). All recipients were harvested at 24 days. No
immunosuppression was administered.
Immunostaining and Morphometric Analysis
The transplanted and native hearts were explanted in all animals.
The harvested hearts were fixed in liquid nitrogen embedded in
OCT compound and kept at –70°C. The primary antibodies were
as follows: rat anti-mouse CD4 monoclonal antibody clone
GK1.5; rat anti-mouse CD8a monoclonal antibody clone 53-6.7;
rat anti-mouse CD11b (Mac-1) clone M1/70 and rat anti-mouse
MOMA-2 monoclonal antibody for monocytes/macrophages; rat
anti-mouse CD25 monoclonal antibody clone 7D4 for interleukin
(IL) 2R; and anti-mouse α-smooth muscle actin monoclonal anti-
body clone 1A4 for smooth muscle cells. All primary antibodies
were purchased from PharMingen (San Diego, Calif), with the
exception of α-smooth muscle actin antibody (Sigma Chemical
Co, St Louis, Mo).
Immunohistochemistry was performed on 5-µm-thick cryostat
sections with the use of an avidin-biotin-peroxidase technique
(Vector Laboratories, Inc, Burlingame, Calif), with 3,3′-
diaminobenzidine as the chromogen. Sections were incubated
with the Avidin-Biotin Complex Solution, Vectastain Elite ABC
kit (Vector Laboratories, Inc). 3,3′-Diaminobenzidine was applied
and subsequently counterstained with Harris hematoxylin.
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The perivascular and vascular region was scored by 2 blinded
observers on a scale of 0 to 4 (0, no staining; 1, scattered individ-
ual cells; 2, focal clusters of cells; 3, multifocal clusters of cells;
and 4, diffuse clusters of cells).
Hematoxylin and eosin stains were performed for routine
examination and scoring of acute cellular rejection by using the
International Society for Heart and Lung Transplantation grading
system. Elastin van Gieson staining was performed for morpho-
metric analysis of arterial intimal proliferation. The morphometric
analysis method previously described by Armstrong and col-
leagues15 was used. The areas of the neointima, media, and lumen
were measured with Optimas 6 software by Media Cybernetics.
The neointima was defined as the area bound by the internal elas-
tic lamina and the lumen. The media was defined as the region
between the internal and external elastic membranes. The lumen
was defined as the clear region in the vessel. Multiple sections
from the middle of the heart were used for analysis. Vessels greater
than 80 µm were measured. An average of 10 vessels per heart
were measured.
Flow Cytometric Analysis
Allografts were homogenized and digested with 10 µg/mL colla-
genase D (Sigma Chemical Co) for 2 hours. The homogenate was
passed through a nylon strainer, and red blood cells were lysed
with red blood cell lysing buffer (Sigma Chemical Co), washed,
and resuspended in phosphate-buffered saline solution. The recip-
ient’s splenocytes were isolated with a nylon cell strainer, and red
blood cells were lysed and subsequently washed. Cells were incu-
bated with Cychrome-labeled CD8 monoclonal antibody, phyco-
erythrin (PE)–labeled CD44 monoclonal antibody, and fluorescein
isothiocyanate (FITC)–labeled CD62 monoclonal antibody for 30
minutes; washed; and analyzed with a COULTER EPICS XL-
MCL Flow Cytometer (Coulter Corporation, Hialeah, Fla). All
antibodies were purchased from PharMingen. Data were presented
as percentages of cells with positive staining calculated as the dif-
ference between the sample’s fluorescence and background non-
specific fluorescence. The cytotoxic phenotype was defined as
CD8 high, CD44 high, CD62 low.
The intracellular cytokine-staining assay was used to deter-
mine the intragraft cytokine profile, identify the cytokine source,
and confirm T-lymphocyte activation. For intracellular cytokine
evaluation, donor heart graft–infiltrating cells were isolated (1-2 ×
106/mL) and subsequently stimulated with PharMingen Activation
Cocktail (10 µL/6 mL; containing phorbol myristate acetate, ion-
omycin, and Brefeldin A) for 4 hours at 37°C. Three separate
experiments were performed at each time point. Only the donor
hearts from the MHC class I mismatched model system were ana-
lyzed in this study. By using 2-color flow cytometric analysis,
graft-infiltrating cells were double stained for cell-surface mark-
ers, as well as for intracellular cytokines. Specifically, the samples
were stained for the presence of cell-surface antigens with FITC-
labeled anti-CD8 monoclonal antibody or FITC-labeled anti-CD4
monoclonal antibody for 30 minutes at 4°C. Samples were
washed, fixed, and permeablized with PharMingen Perm/Fix solu-
tion for 30 minutes at 4°C. The cells were washed in permeabliz-
ing buffer and incubated with either PE-labeled IL-2 monoclonal
antibody, PE-labeled IFN-γ monoclonal antibody, PE-labeled IL-4
monoclonal antibody, or PE-labeled IL-10 monoclonal antibody
for 30 minutes at 4°C. After 2 washes with permeablizing buffer,
the cells were resuspended in phosphate-buffered saline. All anti-
bodies were purchased from PharMingen. Data were presented as
percentages of cells with positive staining calculated as the differ-
ence between the sample’s fluorescence and background nonspe-
cific fluorescence.
Statistical Analysis
All results were expressed as means ± SEM. Statistical analyses
were performed with a paired t test.
Results
Histologic and Morphometric Analysis of Vascular
Lesions in an MHC Class I Mismatched Model
All cardiac isografts and allografts had palpable contractions
at the time of harvest. Cardiac allografts did not have an
ISHLT rejection score of greater than 1B. Cardiac isografts
(controls) did not show either acute rejection or CAV. Intimal
thickening was first notable in allografts harvested at 14 days
(12.0% ± 4.0%, P < .05, Table 1). The extent of intimal pro-
liferation continued to increase when 30-day allografts were
examined (44.0% ± 4.9%, P < .05, Table 1, Figure 1).
Early vascular lesions were characterized by a predomi-
nately inflammatory cell component, with minimal smooth
muscle cell proliferation. Specifically, T lymphocytes and
macrophages infiltrated the cardiac allograft as early as 7
days. The majority of T lymphocytes at all time points were
CD8+ lymphocytes, which were initially scattered through
the interstitium. At 14 days after transplantation, CD8+ lym-
phocytes localized to the perivascular area (Figure 1, A).
CD4+ lymphocytes also demonstrated a similar pattern of
perivascular localization by 14 days after transplantation. At
early time points, monocytes-macrophages were localized
in the interstitium and perivascular areas. In advanced
lesions a large number of macrophages were found within
the expanded intima and accounted for the majority of
mononuclear cells within the lesion.
The cellular characteristics of the lesions described in
this murine model of CAV appear similar to those identified
in human models. The cellular constituents in human
TABLE 1. Intimal proliferation in donor hearts (n = 6 for all
groups)
Group Days Donor Recipient Intimal thickening (%)
I 1 B10.A B10.BR 0.0 ± 0.0
II 7 B10.A B10.BR 0.0 ± 0.0
III 14 B10.A B10.BR 12.0 ± 4.0*
IV 30 B10.A B10.BR 44.0 ± 4.9*
V 24 bm12 C57BL/6 50.0 ± 7.0
VI 24 bm12 CD8 –/– 19.0 ± 6.0†
*P < .05 versus group I.
†P < .05 versus group V.
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lesions have been described immunohistochemically as
both CD4+ and C8+ lymphocytes, macrophages, and
smooth muscle cells.16
Activation Status of CD8+ Lymphocytes
To identify the activation status of the graft-infiltrating
CD8+ lymphocytes, we looked at markers associated with
CD8+ lymphocyte cytotoxicity (CD8+/CD62 low/CD44
high)17 using flow cytometric analysis. The graft-infiltrat-
ing CD8+ lymphocytes expressed markers associated with
cytotoxicity after transplantation (CD62 low/CD44 high) at
all examined time points (Table 2).
Relative Contribution of Graft-infiltrating CD4+
Versus CD8+ Lymphocyte Cytokine Staining
The preceding experiments have established that the CD8+
lymphocytes had localized to the perivascular area, were
activated, and expressed markers of cytotoxicity before the
development of CAV. Intracellular cytokine assays were
performed on the graft-infiltrating CD8+ and CD4+ lym-
phocytes to determine their contribution to the intragraft
cytokine profile. Representative cytokines of both TH1 (IL-
2 and IFN-γ) and TH2 (IL-4 and IL-10) type were used.
At all time points, CD8+ lymphocytes were the predomi-
nant graft-infiltrating T-lymphocyte subset in this MHC class
I mismatched model (Table 3). Moreover, a greater percent-
age of CD8+ lymphocytes produced IL-2 and IFN-γ (Table
3). These findings suggest that CD8+ lymphocytes are the
primary source of IFN-γ, which is known to cause CAV.18,19
Histologic and Morphometric Analyses of Vascular
Lesions in an MHC Class II Mismatched Model
Similar to the MHC class I mismatched model, all cardiac
allografts and isografts in the MHC class II mismatched
Figure 1. Immunostaining and intimal thickening in donor hearts transplanted into recipient mice. A, B10.A donors
transplanted into B10.BR mice. There was an extensive amount of CD8+ T lymphocytes localized primarily to the
perivascular area. B, B10.A donors transplanted into B10.BR recipients had severe intimal lesions. C, B6.C-H2bm12
donor hearts transplanted into C57BL/6 (wild-type) recipients also had severe intimal lesions. D, B6.C-H2bm12 donor
hearts transplanted into CD8 –/– knockout recipients (CD4+ lymphocytes present) had less severe intimal lesions
compared with the donor hearts transplanted into wild-type recipients.
TABLE 2. Graft-infiltrating cytotoxic CD8+ lymphocytes in
transplanted hearts (B10.A donor hearts transplanted into
B10.BR recipients)
CD8 lymphocytes
CD8 lymphocytes demonstrating cytotoxicity markers
Days (% graft-infiltrating cells) (CD8+/CD44 high/CD62 low; %)
7 34.0 ± 3.0 77.0 ± 3.0
14 23.0 ± 2.0 94.0 ± 1.0
30 18.0 ± 4.0 95.0 ± 3.0
Data represent the percentage of CD8+ lymphocytes positive for markers
associated with cytotoxicity (CD8+/CD44 high/CD62 low) at each time
point. Data are representative of 3 replicate experiments.
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model had palpable contractions at the time of harvest at 24
days. The ISHLT rejection score of allografts ranged from
1B to 3A. Cardiac isografts (controls) did not show either
acute rejection or CAV. The immunohistochemical analysis
of vascular lesions in the MHC class II model was similar
to the MHC class I model. The cellular infiltrate of intimal
lesions consisted of CD4+/CD8+ lymphocytes, monocytes-
macrophages, and smooth muscle cells. CD4+ and CD8+
lymphocytes were both within the intimal lesions and in the
perivascular areas in equal numbers. The extent of intimal
lesions in the donor hearts transplanted into the wild-type
recipients was 50.0% ± 7.0% at 24 days (Table 1, Figure 1,
C). In contrast, the severity of intimal lesions in donor
hearts transplanted into CD8 –/– knockout recipients was
substantially less at 24 days (19.0% ± 6.0%, P < .05, Table
1, Figure 1, D). The absence of CD8+ lymphocytes was
confirmed by means of flow cytometric analysis of both
splenocytes of CD8 –/– knockout recipients and the graft-
infiltrating cells of the donor hearts. 
Discussion
In this study we used 2 nonimmunosuppressed models of
CAV to further delineate the role of CD8+ lymphocytes dur-
ing chronic rejection of vascularized cardiac allografts. The
findings in this model illustrate that CD8+ lymphocytes (1)
localize in the perivascular area before the development of
intimal lesions, (2) express markers of cytotoxicity, and (3)
produce proinflammatory cytokines, such as IFN-γ, which
is known to play a pivotal role in CAV development.18,19
Furthermore, donor hearts transplanted into CD8 –/–
knockout recipients had markedly less severe intimal
lesions. Therefore the findings of this study demonstrate an
important role for CD8+ lymphocytes in CAV development.
In acute cellular rejection of allografts, it is currently
accepted that both CD4+ and CD8+ lymphocytes can medi-
ate cellular injury.20,21 In chronic rejection of allografts,
only the role of CD4+ lymphocytes is well established.22-24
However, there is limited and yet conflicting information on
the role of CD8+ lymphocytes in chronic rejection.5,9,10 The
findings of this study substantiate a significant contributory
role for CD8+ lymphocytes in CAV by demonstrating (1) a
temporal relationship between CD8+ lymphocyte recruit-
ment and CAV development, (2) the presence of activated
graft-infiltrating CD8+ lymphocytes, (3) the production of
IFN-γ by graft-infiltrating CD8+ lymphocytes, and (4) a
marked decline in intimal lesion development in the
absence of CD8+ lymphocytes.
To define the precise mechanism of CD8+ lymphocyte
contribution to CAV development, we assayed the graft-
infiltrating CD8+ lymphocytes for their known effector
functions. CD8+ lymphocytes render their effector function
directly, by inducing vessel wall injury (cytotoxicity), or
indirectly, through the secretion of cytokines. Among the
inflammatory cytokines, IFN-γ has been shown to play a
pivotal role in CAV development.18,19 The serologic neu-
tralization or genetic absence of IFN-γ has been shown to
markedly reduce the extent of CAV in murine models.18,19
IFN-γ may contribute to CAV development directly,
through the activation of macrophages, or indirectly,
through the upregulation of donor MHC antigens, with sub-
sequent T-lymphocyte activation.18,19,22-25 Moreover,
Tellides and colleagues26 have recently reported that IFN-γ
alone can induce arteriosclerotic changes in either swine or
human carotid loops transplanted into immunodeficient
mouse recipients. The current study provides evidence that
the mechanism of CD8+ lymphocyte’s contribution to CAV
development is through both cytotoxic activity and elabora-
tion of IFN-γ.
The findings of this study are especially timely and rele-
vant, given the recent reported observations with costimula-
tory blockade therapy.27-30 Costimulatory molecule
signaling is required to activate T lymphocytes.30
Significant strides have been made toward donor-specific
tolerance through costimulatory blockade therapy.27-30
Given the central role of CD4+ lymphocytes in both acute
and chronic rejection, this form of therapy has been con-
TABLE 3. Intracellular cytokine staining of graft-infiltrating cells in transplanted hearts (B10.A donor hearts transplanted
into B10.BR recipients)
Day 7 Day 14 Day 30
CD4 CD8 CD4 CD8 CD4 CD8
GIC (%) 0.3 ± 0.1 34.0 ± 3.0 1.0 ± 0.8 23.0 ± 2.0 3.0 ± 3.0 18.0 ± 4.0
IL-2 (%) 19.0 ± 6.0 25.0 ± 7.0 3.0 ± 3.0 7.0 ± 1.0 7.0 ± 7.0 12.0 ± 4.0
IFN (%) 8.0 ± 5.0 63.0 ± 2.0 9.0 ± 6.0 35.0 ± 1.0 5.0 ± 5.0 44.0 ± 3.0
IL-4 (%) 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
IL-10 (%) 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
Data represent the percentage of each T lymphocyte subset positive for intracellular cytokine staining at each time point. Data are representative of 3
replicate experiments. GIC, Graft-infiltrating cells.
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ventionally directed against CD4+ lymphocyte costimula-
tory molecules, such as CD28 and CD40 ligand. Multiple
experimental and, more recently, clinical studies have
demonstrated the efficacy of costimulatory blockade in pre-
venting acute rejection and prolonging allograft survival.27-30
However, long-lasting allografts still demonstrate manifes-
tations of chronic rejection, ultimately leading to graft fail-
ure.20-23 Given the efficacy of costimulatory blockade in
controlling CD4+ lymphocyte alloreactivity, it has been
suggested that CD8+ lymphocytes may be responsible for
the development of chronic rejection in the aforementioned
studies.12,29-30 The findings of the current study substantiate
a participating role for CD8+ lymphocytes in the pathogen-
esis of chronic rejection.
Optimal activation and proliferation of CD8+ lympho-
cytes, like CD4+ lymphocytes, require the delivery of sig-
nals through both the T-cell receptor and a costimulatory
molecule.28 Recent reports suggest that CD8+ lymphocytes
can be activated independently of CD40 ligand and CD28
costimulatory pathways.13,31,32 CD8+ lymphocyte activation
may include the use of alternate costimulatory pathways,
including an inducible co-stimulator (ICOS), intercellular
adhesion molecule 1 (ICAM-1), and 4-1BB.33-36 We have
recently observed that the costimulatory molecule 4-1BB
provides preferential CD8+ lymphocyte costimulation in the
MHC class II mismatched model system (unpublished
data). The 4-1BB receptor, a member of the tumor necrosis
factor receptor family, is rapidly expressed on T lympho-
cytes after antigen/T-cell receptor binding.34,36 In vitro
studies illustrate that 4-1BB costimulation markedly
enhances CD8+ lymphocyte proliferation, IFN-γ produc-
tion, and cytotoxicity.34,36 Given the importance of CD8+
lymphocytes in chronic rejection, blockade of CD8+ lym-
phocyte–specific costimulatory molecules may be a neces-
sary adjunct to the current costimulatory blockade regimen
in preventing chronic rejection.
In conclusion, this study confirms the role of CD8+ lym-
phocytes and offers a mechanism for their contribution to
chronic rejection. Knowledge of the precise contributions of
CD8+ lymphocytes in CAV development will provide a
framework for the design of rational therapies for chronic
rejection in all solid organ transplants. Specifically, combi-
nation therapies that target CD8+ lymphocytes, in addition to
CD4+ lymphocytes, with costimulatory molecule blockade,
may prove necessary in the prevention of chronic rejection.
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